Resolutions at Pharmacolog AB’s (publ) extraordinary general meeting August 24 2022
The shareholders of Pharmacolog in Uppsala AB (publ) held the Extraordinary General Meeting on August 24, 2022 in Uppsala. (information below in Swedish only)
Styrelse
Stämman beslutade om nyval av Björn Varnestig som styrelseledamot för en mandattid som sträcker sig fram till slutet av nästa årsstämma.
Noterades att Olof Johansson har meddelat att han avgår som styrelseledamot i bolaget i samband med den extra bolagsstämman. Styrelsen kommer således bestå av styrelseordförande Erik Hedlund samt styrelseledamöterna Carl-Johan Spak, Ragnar Linder, och Björn Varnestig för tiden intill nästa årsstämma.
For more information contact:
Mats Högberg, CEO
Email: mats.hogberg@pharmacolog.com
Phone: +46 70-546 50 21
About Pharmacolog AB
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™.
Further information regarding the company is available at www.pharmacolog.com.
The company's Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.
